Brief: Ascentage Pharma Announces IND Clearance By The US FDA For First-In-Human Study Of Novel EED Inhibitor APG-5918
30/06/2022 03:43
June 29 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA ANNOUNCES IND CLEARANCE BY THE US FDA FOR
FIRST-IN-HUMAN STUDY OF NOVEL EED INHIBITOR APG-5918
Source text for Eikon: ID:nPn1RY4SFa
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up